Article (Scientific journals)
A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis.
Hiligsmann, Mickaël; Evers, Silvia M.; Ben Sedrine, Wafa et al.
2015In PharmacoEconomics, 33 (3), p. 205-224
Peer Reviewed verified by ORBi
 

Files


Full Text
A systematic review of cost-effectiveness analysis of drugs for postmenopausal osteoporosis.pdf
Publisher postprint (470.13 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] BACKGROUND: Given the limited availability of healthcare resources and the recent introduction of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in postmenopausal osteoporosis remains and even increases. OBJECTIVE: This study aims to identify all recent economic evaluations on drugs for postmenopausal osteoporosis, to critically appraise the reporting quality, and to summarize the results. METHODS: A literature search using Medline, the National Health Service Economic Evaluation database and the Cost-Effectiveness Analysis Registry was undertaken to identify original articles published between January 1, 2008 and December 31, 2013. Studies that assessed cost effectiveness of drugs in postmenopausal osteoporosis were included. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement was used to assess the quality of reporting of these articles. RESULTS: Of 1,794 articles identified, 39 studies fulfilled the inclusion criteria. They were conducted in 14 different countries and nine active interventions were assessed. When compared with no treatment, active osteoporotic drugs were generally cost effective in postmenopausal women aged over 60-65 years with low bone mass, especially those with prior vertebral fractures. Key drivers of cost effectiveness included individual fracture risk, medication adherence, selected comparators and country-specific analyses. Quality of reporting varied between studies with an average score of 17.9 out of 24 (range 7-21.5). CONCLUSION: This review found a substantial number of published cost-effectiveness analyses of drugs in osteoporosis in the last 6 years. Results and critical appraisal of these articles can help decision makers when prioritizing health interventions and can inform the development of future economic evaluations.
Disciplines :
General & internal medicine
Author, co-author :
Hiligsmann, Mickaël ;  Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Evers, Silvia M.
Ben Sedrine, Wafa
Kanis, John A.
Ramaekers, Bram
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Silverman, Stuart
Wyers, Caroline E.
Boonen, Annelies
Language :
English
Title :
A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis.
Publication date :
2015
Journal title :
PharmacoEconomics
ISSN :
1170-7690
eISSN :
1179-2027
Publisher :
Adis International, Auckland, New Zealand
Volume :
33
Issue :
3
Pages :
205-224
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 17 November 2014

Statistics


Number of views
115 (21 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
77
Scopus citations®
without self-citations
53
OpenCitations
 
67

Bibliography


Similar publications



Contact ORBi